Results 101 to 110 of about 13,963,189 (308)

Comparison of Treatment Outcomes among Second-Line Antiretroviral Regimens in HIV/AIDS Patient

Jurnal Manajemen dan Pelayanan Farmasi, 2018
Antiretroviral (ARV) therapy can increase life expectancy of people living with HIV/AIDS (PLWHA). If the therapy fails and causes severe toxicity to first-line ARV, the first-line ARV regimen is switched to the second line.
Winda Dwi Puspitasari, Nanang Munif Yasin, Fita Rahmawati   +2 more
doaj   +1 more source

Going viral − Virus‐targeting nanobodies for research, diagnostics and therapy

FEBS Letters, EarlyView.
The increasing prevalence of viral diseases represents a major threat for global human health. Nanobodies, small binding fragments derived from camelid heavy‐chain antibodies, offer versatile tools for viral research, diagnostics, and antiviral therapy.
Domenic Ebert, Ulrich Rothbauer
wiley   +1 more source

How structural disorder and polyelectrolyte properties of prothymosin α enable its large interactome

FEBS Letters, EarlyView.
In this review, complexes of the fully disordered and highly negatively charged prothymosin α are collected, described, and discussed. Linked to its poly‐electrostatic character, prothymosin α engages a large interactome through multiple different binding modes ranging from fully disordered complexes to short linear motif (SLiM)‐driven interactions ...
Ketty C. Tamburrini, Freia S. Buus, Benjamin Schuler, Birthe B. Kragelund   +3 more
wiley   +1 more source

Is there a difference in rhythm outcome between patients undergoing first line versus second line paroxysmal atrial fibrillation ablation?

PLoS ONE, 2018
BackgroundCatheter ablation of atrial fibrillation (AF) is an established second line therapy for patients with symptomatic paroxysmal AF (PAF) and may be considered as a first line therapy in selected patients who are highly symptomatic, considering ...
Martin Manninger, Jakob Ebner, David Zweiker, Raphael Sieghartsleitner, Bernadette Mastnak, Egbert Bisping, Peter Lercher, Rita Riedlbauer, Brigitte Rotman, Helmut Brussee, Daniel Scherr   +10 more
doaj   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

Spotlight on ramucirumab in the treatment of nonsmall cell lung cancer: design, development, and clinical activity

Lung Cancer: Targets and Therapy, 2017
Manuel Cobo,1 Vanesa Gutiérrez,1 Rosa Villatoro,2 Jose Manuel Trigo,1 Inmaculada Ramos,1 Omar López,1 María Ruiz,1 Ana Godoy,1 Irene López,1 Macarena Arroyo3 1Medical Oncology Department, Hospital Universitario Málaga ...
Cobo M, Gutiérrez V, Villatoro R, Trigo JM, Ramos I, López O, Ruiz M, Godoy A, López I, Arroyo M   +9 more
doaj  

Baseline clinical characteristics of NSCLC patients receiving nivolumab as second-or-more-line therapy.

, 2019
Baseline clinical characteristics of NSCLC patients receiving nivolumab as second-or-more-line therapy.
Alain Vergnenègre (6989990), Boris Melloni (6989981), Matthieu Dusselier (6989972), Nellie Delacourt (382788), Charlotte Vergnenègre (6989984), Elise Deluche (6876620), Rémi Veillon (6989987), Julia Ballouhey (6989975), Thomas Egenod (6989978)   +8 more
core   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy.

, 2006
BACKGROUND: Epothilones and taxanes interfere with microtubule function. Ixabepilone, which is an epothilone-B analog, has activity against taxane-resistant cell lines and as first-line therapy for men with hormone-refractory prostate carcinoma (HRPC ...
Weinberg, Vivian K, Oh, William K, Kelly, W Kevin, Galsky, Matthew D, Rohs, Nicholas C, Rosenberg, Jonathan E, Small, Eric J   +6 more
core   +1 more source

Second-line therapy of metastatic bladder cancer

, 2012
This article summarizes the contemporary standards as well as updated study results for second-line systemic therapy for metastatic and urothelial carcinoma pretreated with cisplatin.
Retz, M;Bokemeyer, C
core